Belgrade, Republic of Serbia

Vjera Pejanovic

This inventor holds 1 USPTO granted patent. Top assignee: Icn Pharmaceuticals, Inc.. Active years: 1999.


% Patents Active = 100.0

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 1999

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Vjera Pejanovic: Innovator in Ribo-C-Nucleosides

Introduction

Vjera Pejanovic is a notable inventor based in Belgrade, RS. She has made significant contributions to the field of biochemistry, particularly in the development of novel procedures for obtaining ribo-C-nucleosides. Her work has implications for various applications in pharmaceuticals and biotechnology.

Latest Patents

Vjera Pejanovic holds a patent for "Procedures for obtaining ribo-C-nucleosides." This patent includes innovative methods for synthesizing compounds such as 2-.beta.-D-ribofuranosylthiazole-4-carboxylamide (tiazofirin) and 2-.beta.-D-ribofuranosylselenazole-4-carboxylamide (sylenazofurin). The procedures involve introducing a cyano group at the 1' position of a ribose and converting it into various functional groups, ultimately leading to the formation of heterocyclic rings.

Career Highlights

Vjera Pejanovic is currently associated with Icn Pharmaceuticals, Inc., where she continues her research and development efforts. Her expertise in nucleoside chemistry has positioned her as a valuable asset in the pharmaceutical industry.

Collaborations

Throughout her career, Vjera has collaborated with esteemed colleagues such as Kandasamy Ramasamy and Arthur F Lewis. These collaborations have further enhanced her research and contributed to the advancement of her projects.

Conclusion

Vjera Pejanovic is a pioneering inventor whose work in ribo-C-nucleosides showcases her innovative spirit and dedication to advancing biochemistry. Her contributions are expected to have a lasting impact on the pharmaceutical field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…